Lifemd Inc Stock Price, News & Analysis

LifeMD reported record revenue of $22.3 million for Q2 2021, marking a 145% increase year-over-year. 93% of revenue came from subscriptions, up from 56% last year. The total telehealth order volume grew by 155%, reaching 199,764 orders. Customer Acquisition Costs (CAC) decreased by 8% sequentially, while new patient acquisitions improved by 11%. Despite a net loss of $16.8 million, LifeMD reiterated its 2021 revenue guidance of $90 million to $100 million, signaling strong market demand and strategic growth initiatives.

LifeMD (NASDAQ: LFMD) announced a partnership with Particle Health to enhance personalized medical care through improved access to patient health records. With access to a database covering over 90% of the U.S. population, licensed providers can leverage comprehensive health data, paving the way for better healthcare outcomes. This strategic alliance aims to simplify healthcare delivery and strengthen patient-provider relationships, ultimately driving the launch of LifeMD's primary care platform.

LifeMD, Inc. (NASDAQ: LFMD) announced a conference call to discuss its second quarter fiscal 2021 financial results on August 12, 2021, at 4:30 p.m. ET. The results will be released prior to the call, and management will host the discussion followed by a Q&A session. LifeMD offers direct-to-patient telehealth services and products nationwide. The call can be accessed via toll-free and international dial-in numbers or streamed online. Interested parties should review the company's SEC filings for risk factors and historical financial data.

LifeMD (NASDAQ: LFMD) has partnered with Axle Health to provide telehealth access to over 150 diagnostic laboratory tests at preferred prices. Patients can complete tests securely in their homes or via local lab service centers. The collaboration aims to transform healthcare delivery by enhancing access to early diagnosis, which is crucial for effective healthcare outcomes. This integration is expected to improve patient services while supporting LifeMD's expansion in virtual primary care offerings.

On June 11, 2021, LifeMD, Inc. (NASDAQ: LFMD) appointed Alexander Mironov as President. Mironov brings over 20 years of experience in business development and M&A in the pharmaceutical sector, with transactions worth over $5 billion. His previous role at Covis Pharma saw revenue growth exceeding 10x. Mironov aims to transform LifeMD's telehealth services. He received options for 200,000 shares at $14.04, vesting over 36 months, plus a performance-based grant of 300,000 restricted shares based on deal contributions.

LifeMD, Inc. (NASDAQ: LFMD) successfully closed a $15 million debt financing with B. Riley Principal Investments, enhancing liquidity and supporting growth in its telehealth business. This marks LifeMD’s first debt financing and strengthens its balance sheet, aligning with its aggressive growth strategy through 2022. CFO Marc Benathen emphasized that the transaction validates LifeMD’s telehealth platform and enables further investment towards profitability. B. Riley views LifeMD as a promising investment, committing to leverage their banking platform for the company’s growth.

LifeMD (NASDAQ: LFMD) has announced its participation in two upcoming conferences: the Capital Peak Advisors Best Ideas Conference on June 2, 2021, at 11:00 am ET and the 2021 LD Micro Invitational XI on June 8, 2021, at 4:30 pm ET. The presentations will include 1x1 meetings for deeper engagement with participants. LifeMD is a direct-to-patient telehealth company offering virtual medical treatment and prescription services across the U.S. For more details, visit LifeMD.com.

LifeMD, Inc. (NASDAQ: LFMD) has announced the voluntary dismissal of two shareholder lawsuits filed against the company, which were considered meritless. The cases, Owens v. LifeMD and Cho v. LifeMD, were filed in the U.S. District Court for the Southern District of New York and formally dismissed on May 18 and 19, 2021. LifeMD remains committed to enhancing access to healthcare through its telemedicine platform. The company emphasizes a focus on transparency, integrity, and patient care.

LifeMD announces the appointment of Dr. Matthew Zipoli as a medical advisor for its tele-dermatology brand, Nava MD. Dr. Zipoli, a leading dermatologist with over 20 years of experience in Mohs Surgery, aims to enhance the brand's development goals. His affiliation with reputable hospitals and teaching credentials at Tufts University School of Medicine underscore his expertise. Chief Medical Officer Dr. Anthony Puopolo emphasizes the expected growth in subscriber base and brand recognition for Nava MD as they optimize their tele-dermatology offerings.